<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308024">
  <stage>Registered</stage>
  <submitdate>4/06/2009</submitdate>
  <approvaldate>16/06/2009</approvaldate>
  <actrnumber>ACTRN12609000463279</actrnumber>
  <trial_identification>
    <studytitle>Does the anti-sickness drug dexamethasone influence immune function in breast surgery?</studytitle>
    <scientifictitle>The influence of antiemetic doses of dexamethasone on postoperative lymphocyte sub-populations after breast surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Immune function</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Granisetron 1mg, Dexamethasone 4mg or 8mg intravenously, single dose, after induction and immediately prior to surgery</interventions>
    <comparator>Granisteron 1mg</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportions of lymphocyte subpopulations on blood analysis</outcome>
      <timepoint>Baseline, 24 hours one week and six weeks after administration of drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Macrophage Inhibitory Factor concentrations</outcome>
      <timepoint>Baseline, 24 hours and 168 hours after administration of drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Females undergoing breast surgery
American Society of Anesthesiologists (ASA) Class I-III</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Current drug therapy with antiemetics, steroids or serotonergic antidepressants
Active infection
Known or suspected metastatic disease
Previous chemotherapy treatment
Patients receiving implants, such as mesh repairs
Allergy/intolerance to any of the study drugs (including renal or hepatic impairment, active peptic ulcer disease, ischaemic heart disease, QT prolongation, major psychiatric illness)
Diabetes mellitus or history of seizures
Participation in any other research trial
Pregnant or possibility of</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment via sealed opaque envelopes</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate>19/04/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/07/2012</actualenddate>
    <samplesize>51</samplesize>
    <actualsamplesize>51</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>11/09/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Clinical A/Professor Tomas Corcoran</primarysponsorname>
    <primarysponsoraddress>Department of Anaesthesia and Pain Medicine,
Royal Perth Hospital,
GPO Box X2213,
Perth,
W.A. 6847.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Perth Hospital Research Department</fundingname>
      <fundingaddress>Royal Perth Hospital,
GPO Box X2213,
Perth,
W.A. 6847</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Kirk Langley</sponsorname>
      <sponsoraddress>Department of Anaesthesia and Pain Medicine,
Royal Perth Hospital,
GPO Box X2213,
Perth,
W.A. 6847.</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dexamethasone is a drug commonly given to prevent postoperative nausea and vomiting.  It also has properties that dampen the body's immune response to infection.  In this study, we propose to examine female patients undergoing breast surgery.  These patients are at high risk of nausea and vomiting and routinely receive drugs to prevent this.  We will give patients one of two drugs, either dolasetron or dexamethasone when they are under anaesthetic.  Blood samples will be taken before and after the drugs to determine the effect that they have on the immune system.  We hope to determine whether dexathasone has an effect on the body's immune system.</summary>
    <trialwebsite />
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress>Royal Perth Hospital,
GPO Box X2213,
Perth,
W.A. 6847</ethicaddress>
      <ethicapprovaldate>5/12/2008</ethicapprovaldate>
      <hrec>EC 2008/194</hrec>
      <ethicsubmitdate>5/11/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Clinical A/Professor Tomas Corcoran</name>
      <address>Department of Anaesthesia and Pain Medicine,
Royal Perth Hospital,
GPO Box X2213,
Perth,
W.A. 6847.</address>
      <phone>+61 8 92241038</phone>
      <fax>+61 8 92241111</fax>
      <email>tomas.corcoran@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Clinical A/Professor Tomas Corcoran</name>
      <address>Department of Anaesthesia and Pain Medicine,
Royal Perth Hospital,
GPO Box X2213,
Perth,
W.A. 6847.</address>
      <phone>+61 8 92241038</phone>
      <fax>+61 8 92241111</fax>
      <email>tomas.corcoran@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Tomas  Corcoran</name>
      <address>Department of Anaesthesia and Pain Medicine, Royal Perth Hospital</address>
      <phone>+61414791151</phone>
      <fax />
      <email>mascor@bigpond.net.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>